Activity ID
14478Expires
December 31, 2026Format Type
EnduringCME Credit
1Fee
$0CME Provider: Clinical Care Options, LLC
Description of CME Course
The goal of this activity is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Schizophrenia
ABMS Member Board Approvals by Type
ABMS Lifelong Learning CME Activity
Psychiatry and Neurology
Commercial Support?
YesNOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Educational Objectives
At the conclusion of this activity, learners should be better able to:
· Identify the mechanisms of action and pharmacokinetic profiles of novel and emerging therapeutic agents for schizophrenia, extending beyond traditional antidopaminergic antipsychotics
· Compare the efficacy and safety data of novel and emerging agents in the treatment of schizophrenia
· Describe the potential of novel antipsychotic therapies to address unmet needs and transform clinical practice in schizophrenia management
Competencies
Medical Knowledge
CME Credit Type
AMA PRA Category 1 Credit
Practice Setting
Inpatient, Outpatient, Rural, Urban, VA/Military
